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The benefits of inhaled corticosteroids (ICS) as dual or triple combination therapy are 
more pronounced in patients with the frequent exacerbating eosinophilic (FEE) 
phenotype of COPD, corresponding to GOLD group D1. The real life study of Suissa 
et al2 looked at a cohort of COPD patients in whom 82% had zero or one prior 
exacerbations, corresponding to GOLD group B. In infrequently exacerbating 
patients one might expect there to be little impact conferred by using an ICS in 
combination with a long acting beta-agonist (LABA).  In such patients using two long 
acting bronchodilators as LABA along with long acting muscarinic antagonist (LAMA) 
has not been shown to be superior to LAMA alone (as tiotropium) in reducing  
exacerbations3. The low prevalence of patients with the FEE phenotype in the 
dataset of Suissa et al would preclude any meaningful post hoc analysis to 
investigate the putative benefits of ICS/LABA over LABA/LAMA. 
We believe a more worthwhile real life study might perhaps be to compare patients 
taking LABA/LAMA versus ICS/LABA/LAMA, especially since randomised controlled 
and real world trials have shown clear superiority of triple therapy compared to 
ICS/LABA on exacerbations4,5. An important point not considered by Suissa et al is 
the impact of different inhaler types in each group, which in turn might exhibit 
potential confounding effects on lung deposition and patient adherence. In this 
regard prospective randomised controlled trials have demonstrated triple therapy to 
be superior to LABA/LAMA when both are taken via the same single dry powder 
inhalers5.
We would therefore suggest extreme caution in extrapolating the findings of Suissa 
et al to patients with the FEE phenotype of COPD, where ICS containing dual or 
triple therapy is likely to be effective. Furthermore their findings of more pneumonias 
with ICS/LABA is likely to be specific to fluticasone propionate due to its increased 
lipophilicity and associated prolonged lung retention1.
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